A 48-weeks national multicenter randomized open clinical trial evaluating tolerance and efficacy of a treatment simplification by lopinavir/ritonavir versus continuation of current treatment in HIV-infected patients with a viral load inferior to 50 copies/mL since 6 months at least
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms KALESOLO
- 26 Jul 2017 Results (n=637) of pooled analysis of NCT00140751, NCT00421551, NCT00946595 trials analysing distribution of ultrasensitive viral load (USVL) and impact of USVL on virological failure presented at the 9th International AIDS Society Conference on HIV Science
- 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Sep 2010 Results have been published in the Journal of Antimicrobial Chemotherapy.